Mineralys Therapeutics (MLYS)
Develops lorundrostat for uncontrolled hypertension and related cardiorenal conditions.
BlackRock Inc. Buys New Position in Mineralys Therapeutics, Inc. $MLYS
BlackRock Inc. purchased a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ: MLYS) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 5,887,038 shares of the company's stock, valued at approximately $158,832,000. BlackRock Inc. owned approximately 7.14% of Mineralys Therapeutics
Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript
Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript
Mineralys Therapeutics Q2 Earnings Call Highlights
Mineralys Therapeutics NASDAQ: MLYS said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date, while reporting a wider second-quarter loss driven largely by a $200 million upfront payment related to its amended agreement with Tanabe Pharma Corp.
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
– PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval – – Appoints accomplished cardiovascular medicine executive Dr. Terry Ferguson as Chief Medical Officer to lead the Company's medical and late-stage clinical activities – – Strengthened balance sheet and enhanced the long-term economics of lorundrostat through strategic financing initiatives and the repurchase of the Tanabe royalty obligation – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision
This clinical-stage biotech focused on hypertension therapies reported a notable insider sale amid strong one-year stock performance.
Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
RADNOR, Pa. , June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami on June 8-10, 2026.
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
RADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an underwritten offering of 5,660,378 shares of its common stock at a price of $26.50 per share. The aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $150.0 million. All of the securities to be sold in the offering are to be sold by Mineralys. The offering is expected to close on or about June 4, 2026, subject to the satisfaction of customary closing conditions.
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
– Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met –
Mineralys' pill cuts blood pressure in kidney disease patients
Mineralys Therapeutics' experimental drug significantly reduced blood pressure in patients with chronic kidney disease, according to new data presented at a major European medical conference on Saturday.
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
- Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease - - In participants with chronic kidney disease and baseline albuminuria, lorundrostat significantly reduced urine albumin-to-creatinine ratio - - Lorundrostat demonstrated a favorable safety profile in participants with and without chronic kidney disease over 12 weeks - RADNOR, Pa.
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease –
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
– Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease –
Mineralys Therapeutics, Inc. (MLYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Mineralys Therapeutics, Inc. (MLYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Mineralys Therapeutics, Inc. (MLYS) Q1 2026 Earnings Call Transcript
Mineralys Therapeutics, Inc. (MLYS) Q1 2026 Earnings Call Transcript
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
– NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced that management will be participating in the Bank of America Securities 2026 Health Care Conference being held in Las Vegas on May 11-14, 2026.
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
RADNOR, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced it will report its financial results from the first quarter ended March 31, 2026, after the financial markets close on Wednesday, May 6, 2026.
David Malcom Rodman Sells 2,170 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) insider David Malcom Rodman sold 2,170 shares of the stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $27.38, for a total value of $59,414.60. Following the sale, the insider directly owned 76,140 shares in the company, valued at
Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?
CEO Jon Congleton sold 75,000 shares for a total transaction value of ~$1.97 million on April 2, 2026. The sale represented 9.61% of direct holdings prior to the transaction, reducing direct ownership to 705,051 shares.